KOREA WHO
-
-
-
Chairman of Celltrion Group
Seo Jung-jin
Returned to Management After 3 Years, Aims to Challenge Big Pharma as a New Drug Developer
-
Last Updated on Jan 17, 2025
-
Chairman of Celltrion Group
Life Summary
Seo Jung-jin is the chairman of Celltrion Group.
He is transforming Celltrion from a biosimilar (biopharmaceutical generic drug) company into a new drug developer.
He was born on October 23, 1957, in Cheongju, Chungcheongbuk-do.
He graduated from Jemulpo High School in Incheon and majored in Industrial Engineering at Konkuk University, where he also earned a master's degree from the Graduate School of Industry.
He began his career at Samsung Electro-Mechanics.
He later moved to the Korea Productivity Center, where he was responsible for consulting Daewoo Motors, eventually being selected as an advisor for planning and finance at Daewoo Motors.
In 1999, he founded "Nexol," the predecessor of Celltrion.
Although he stepped down from management as Celltrion Group shifted to a professional management system, he returned to lead the company.
He aims to make the company a global pharmaceutical leader with KRW 10 trillion (US$ 7.2 billion) in revenue by 2030.
When things do not go smoothly, he tackles problems hands-on to find solutions. He enjoys work to the extent that he considers business trips abroad a hobby.
#SeoJungJin #CelltrionGroup #biosimilar #newdrugdevelopment #pharmaceutical #DaewooMotors #SamsungElectroMechanics #globalpharma #KoreanCEO #businessstrategy
He is transforming Celltrion from a biosimilar (biopharmaceutical generic drug) company into a new drug developer.
He was born on October 23, 1957, in Cheongju, Chungcheongbuk-do.
He graduated from Jemulpo High School in Incheon and majored in Industrial Engineering at Konkuk University, where he also earned a master's degree from the Graduate School of Industry.
He began his career at Samsung Electro-Mechanics.
He later moved to the Korea Productivity Center, where he was responsible for consulting Daewoo Motors, eventually being selected as an advisor for planning and finance at Daewoo Motors.
In 1999, he founded "Nexol," the predecessor of Celltrion.
Although he stepped down from management as Celltrion Group shifted to a professional management system, he returned to lead the company.
He aims to make the company a global pharmaceutical leader with KRW 10 trillion (US$ 7.2 billion) in revenue by 2030.
When things do not go smoothly, he tackles problems hands-on to find solutions. He enjoys work to the extent that he considers business trips abroad a hobby.
#SeoJungJin #CelltrionGroup #biosimilar #newdrugdevelopment #pharmaceutical #DaewooMotors #SamsungElectroMechanics #globalpharma #KoreanCEO #businessstrategy